Business

Biocon profit share on adalimumab biosimilar extended to global markets

Biocon profit share on adalimumab biosimilar extended to global markets "Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets," the statement added.

from Moneycontrol Business News
Read The Rest:moneycontrol...

Realted Posts